Steve Arnold joined Amicus in November 2023 and currently serves as Chief, Head of Global Rare Disease. He brings 30 years of experience in the healthcare industry to Amicus, having previously served in numerous executive leadership roles responsible for driving commercial growth and enhancing operational efficiency. Prior to Amicus, Steve served as President, Global Markets for Albireo Pharma Inc., a rare pediatric liver disease company, where he led rare disease product launches across all markets and was influential in the substantial acceleration of the Albireo U.S. business, until its sale to Ipsen in March 2023. Previously, he spent six years at Intercept Pharmaceuticals in various senior and executive roles in which he notably led the successful launch and commercialization in Primary biliary cholangitis (PBC), a rare liver disease. Before that, he served as the Managing Director, British and Irish Isles for UCB, following a 6-year tenure with Gilead Sciences in leadership roles of increasing seniority, including General Manager Canada, and Business Unit Director for HIV in the U.K.
Steve received an M.A. in Psychology from the University of St. Andrews.